Crispr Therapeutics AG Cash Flow Quality Index
Crispr Therapeutics AG cash flow quality index. Crispr Therapeutics AG (CRSP) has a Cash Flow Quality Index of -1.08x as of December 2023. Operating cash flow of $-96.07 Million is below net income of $89.35 Million, suggesting accrual-heavy earnings not yet converted to cash. See Crispr Therapeutics AG leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Crispr Therapeutics AG (2019–2021)
Cash flow quality index of Crispr Therapeutics AG from 2019 to 2021. Historical Cash Flow Quality Index for Crispr Therapeutics AG across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore CRSP cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Crispr Therapeutics AG Cash Flow Quality Index by Year (2019–2021)
Crispr Therapeutics AG cash flow quality index by year from 2019 to 2021. Year-by-year earnings quality comparison for Crispr Therapeutics AG. For the full cash flow conversion analysis, see cash efficiency ratio of Crispr Therapeutics AG.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 1.43x | $538.97 Million | $377.66 Million | ▲ +68.3% |
| 2019 | 0.85x | $56.68 Million | $66.86 Million | — |